HC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 452.49% from the stock’s current price.

A number of other brokerages also recently weighed in on ZNTL. Wells Fargo & Company decreased their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. UBS Group reduced their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Wedbush reissued a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $1.81 on Thursday. The stock has a market capitalization of $128.99 million, a price-to-earnings ratio of -0.73 and a beta of 1.75. Zentalis Pharmaceuticals has a 52 week low of $1.61 and a 52 week high of $16.27. The stock has a fifty day moving average of $2.04 and a 200-day moving average of $2.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. The business had revenue of $26.90 million for the quarter. As a group, equities analysts forecast that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

Insider Buying and Selling

In other news, Director Jan Skvarka bought 60,000 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now directly owns 149,551 shares of the company’s stock, valued at $257,227.72. This represents a 67.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Ingmar Bruns purchased 20,000 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were purchased at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the transaction, the insider now directly owns 36,629 shares in the company, valued at approximately $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Almitas Capital LLC raised its position in shares of Zentalis Pharmaceuticals by 69.3% in the fourth quarter. Almitas Capital LLC now owns 1,626,896 shares of the company’s stock valued at $4,929,000 after purchasing an additional 665,968 shares during the period. Primecap Management Co. CA raised its holdings in Zentalis Pharmaceuticals by 1.5% during the 4th quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company’s stock valued at $4,608,000 after acquiring an additional 22,600 shares during the period. Verition Fund Management LLC raised its holdings in Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after acquiring an additional 951,500 shares during the period. Geode Capital Management LLC lifted its position in shares of Zentalis Pharmaceuticals by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company’s stock worth $3,979,000 after acquiring an additional 20,864 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its holdings in shares of Zentalis Pharmaceuticals by 9.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,239,459 shares of the company’s stock worth $3,756,000 after acquiring an additional 110,882 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.